Raised CAPLYTA full year 2024 net product sales guidance range to $665 to $685 million. Narrowed full year 2024 SG&A expense guidance range to $490 to $510 million and full year 2024 R&D expense guidance range to $220 to $230 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- ITCI Upcoming Earnings Report: What to Expect?
- Intra-Cellular price target raised to $95 from $92 at Morgan Stanley
- Intra-Cellular announces presentations at 2024 ECNP Congress
- Broadcom AI results fail to enthuse the Street: Morning Buzz
- Piper upgrades Intra-Cellular on potential in major depressive disorder